-
公开(公告)号：US20050244429A1
公开(公告)日：2005-11-03
申请号：US10519531
申请日：2003-06-27
Applicant: Thomas Folks , Irvin Chen
Inventor： Thomas Folks , Irvin Chen
IPC: A61K39/12 , C07K14/16 , C12N7/00 , C12N15/86 , C12N15/867
CPC classification number: C07K14/005 , A61K2039/5256 , C12N15/86 , C12N2740/16122 , C12N2740/16222 , C12N2740/17043
Abstract: The present invention provides a vector or vector containing composition comprising a spumavirus backbone and a antigen-encoding nucleic acid. The present invention also provides methods of treating or preventing a condition resulting from a vital, bacterial, or parasitic infection in a subject comprising administering to the subject an effective amount of the vector or vector containing composition comprising a spumavirus backbone and an antigen-encoding nucleic acid. Also provided in the present invention are methods of treating a condition resulting from a cancer in a subject comprising administering to the subject an effective amount of the vector or vector containing composition comprising a spumavirus backbone and an antigen-encoding nucleic acid.
Abstract translation: 本发明提供了一种载体或含载体的组合物，其包含一种真菌病毒骨架和一种抗原编码核酸。 本发明还提供了治疗或预防由受试者引起的重要，细菌或寄生虫感染的病症的方法，包括向受试者施用有效量的含有疫苗主链和抗原编码核酸的载体或载体的组合物 酸。 本发明还提供了治疗受试者中由癌症引起的病症的方法，所述方法包括给受试者施用有效量的包含真菌病毒骨架和抗原编码核酸的载体或载体的组合物。
-
2.发明申请VECTOR ENCODING THERAPEUTIC POLYPEPTIDE AND SAFETY ELEMENTS TO CLEAR TRANSDUCED CELLS 审中-公开编码治疗性多肽的载体和清除转导细胞的安全性元素公开(公告)号：US20100233200A1
公开(公告)日：2010-09-16
申请号：US12532572
申请日：2008-03-27
Applicant: Jeffrey A. Medin
Inventor： Jeffrey A. Medin
IPC: A61K39/385 , C12N15/74 , A61K31/7088 , C12N5/071 , A61K35/12 , A61P37/06
CPC classification number: A61K48/005 , A61K47/6825 , A61K47/6849 , A61K48/0083 , A61K2039/505 , C07K16/2866 , C07K2319/55 , C07K2319/74 , C12N9/1211 , C12N15/86 , C12N2740/15033 , C12N2740/15043 , C12N2740/17033 , C12N2740/17043 , C12N2750/14133 , C12N2750/14143 , C12N2799/027
Abstract: A composition comprising: a stably integrating delivery vector; an modified mammalian thymidylate kinase (tmpk) activator polynucleotide wherein the modified mammalian tmpk polynucleotide encodings a modified mammalian tmpk polypeptide that increases phosphorylation of converts a prodrug relative to phosphorylation of the prodrug by wild-type mammalian tmpk polypeptide to a drug; and/or a targeting polynucleotide encoding a cell surface polypeptide that selectively binds a toxic binding agent. The disclosure also relates to use of these compositions in methods of treatment of diseases such as Fabry disease.
Abstract translation: 一种组合物，其包含：稳定整合递送载体; 修饰的哺乳动物胸苷酸激酶（tmpk）激活剂多核苷酸，其中修饰的哺乳动物tmpk多核苷酸编码修饰的哺乳动物tmpk多肽，其增加将前体药物相对于通过野生型哺乳动物tmpk多肽磷酸化的药物转化为药物的磷酸化; 和/或编码选择性结合有毒结合剂的细胞表面多肽的靶向多核苷酸。 本公开还涉及这些组合物在治疗诸如法布里病的疾病的方法中的用途。
-
公开(公告)号：US20030148509A1
公开(公告)日：2003-08-07
申请号：US10272394
申请日：2002-10-15
Applicant: The Govt. of the USA, as represented by the secretary, Dept. of Health and Human Services
Inventor： Margaret E. Callahan , Thomas M. Folks , Paul Sandstrom , Shambavi Subbarao , Jennifer Brown , Walid Heneine , William M. Switzer
IPC: C12Q001/68 , C12P021/06 , C12N007/00 , C12N007/01 , C12N015/00 , C12N015/09 , C12N015/63 , C12N015/70 , C12N015/74
CPC classification number: C07K14/005 , A61K48/00 , C12N7/00 , C12N15/86 , C12N2740/17021 , C12N2740/17022 , C12N2740/17043
Abstract: The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.
-
公开(公告)号：US11813318B2
公开(公告)日：2023-11-14
申请号：US16507589
申请日：2019-07-10
Inventor： David W. Russell , Roli K. Hirata
CPC classification number: A61K39/0005 , A61K35/28 , C07K14/70539 , A61K35/12 , A61K2039/515 , C07K2319/00 , C12N2740/17043 , C12N2750/14143 , C12N2800/30
Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.
-
5.发明申请FOAMY VIRAL VECTOR COMPOSITIONS AND METHODS FOR THE MANUFACTURE OF SAME 审中-公开FOAMY VIRAL VECTOR COMPOSITIONS AND METHODS FOR MANUIFACTURE OF SAME公开(公告)号：US20160257972A1
公开(公告)日：2016-09-08
申请号：US15041087
申请日：2016-02-11
Applicant: Children's Hospital Medical Center
Inventor： Johannes C.M. van der Loo , David William Russell , Punam Malik , Md Nasimuzzaman
CPC classification number: C12N15/86 , C12N7/00 , C12N2740/17043 , C12N2740/17051
Abstract: Disclosed are methods of preparing FV vector particles. In some aspects, the disclosed methods may include the steps of transfecting a population of eukaryotic cells by contacting said population of eukaryotic cells with one or more transfection reagents to form a transfection mixture, and incubating the transfection mixture to form a transfected cell population; harvesting the FV vector particles from said transfected cell population; purifying the FV vector particles; and concentrating the FV vector particles.
Abstract translation: 公开了制备FV载体颗粒的方法。 在一些方面，所公开的方法可以包括通过将所述真核细胞群与一种或多种转染试剂接触以转染真核细胞群来形成转染混合物，并孵育转染混合物以形成转染细胞群的步骤; 从所述转染的细胞群体中收获FV载体颗粒; 纯化FV载体颗粒; 并浓缩FV载体颗粒。
-
Patent Agency Ranking
公开(公告)号：US20140134195A1
公开(公告)日：2014-05-15
申请号：US14111837
申请日：2012-04-18
Applicant: David W. Russell
Inventor： David W. Russell
CPC classification number: A61K39/0005 , A61K35/12 , A61K35/28 , A61K2039/515 , C07K14/70539 , C07K2319/00 , C12N2740/17043 , C12N2750/14143 , C12N2800/30
Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.
Abstract translation: 本发明提供分离的灵长类动物细胞，优选包含β-2微球蛋白（B2M）基因中遗传工程化破坏的人细胞，其导致MHC I类表达和功能的不足。 还提供了使用细胞进行移植和治疗疾病状况的方法。
-
公开(公告)号：US06623952B1
公开(公告)日：2003-09-23
申请号：US09830616
申请日：2001-09-05
Applicant: Paul A. Sandstrom , Thomas M. Folks , Walid M. Heneine , William M. Switzer , Jennifer Brown
Inventor： Paul A. Sandstrom , Thomas M. Folks , Walid M. Heneine , William M. Switzer , Jennifer Brown
IPC: C12N700
CPC classification number: C12N15/86 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/525 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N2740/17021 , C12N2740/17022 , C12N2740/17032 , C12N2740/17043
Abstract: The present invention comprises a spumavirus isolated from a human. More specifically, the spumavirus of the present invention was isolated from a human who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.
Abstract translation: 本发明包括从人分离的真菌病毒。 更具体地，将本发明的真菌病毒与暴露于非人灵长类动物的人分离。 重要的是，本发明的真菌病毒或针对该病毒的抗体可用于检测体液中的真菌病毒或抗体的存在，相关病毒的致病性研究以及用于基因治疗的载体。 由于存在快速分裂的细胞和重组活病毒疫苗接种，本发明的真菌病毒也可用于治疗人体中的病症。
-
公开(公告)号：US20160222410A1
公开(公告)日：2016-08-04
申请号：US14915434
申请日：2014-09-02
Applicant: CELLECTIS
Inventor： Andrew SCHARENBERG , Julianne SMITH , Roman GALETTO
CPC classification number: C12N15/86 , C12N7/00 , C12N2740/17043 , C12N2740/17052
Abstract: The present invention relates to viral transformation method, particularly foamy virus-mediated transformation method. The present invention relates to the transfer of transgene into cells by the safe and efficient transfer of RNA encoding foamy components. The present invention has therefore therapeutic interest, especially in the field of gene therapy.
Abstract translation: 本发明涉及病毒转化方法，特别是泡沫病毒介导的转化方法。 本发明涉及通过安全有效地转移编码泡沫组分的RNA将转基因转移到细胞中。 因此，本发明具有治疗兴趣，特别是在基因治疗领域。
-
公开(公告)号：US06787333B2
公开(公告)日：2004-09-07
申请号：US10272394
申请日：2002-10-15
Applicant: Margaret E. Callahan , Thomas M. Folks , Paul Sandstrom , Shambavi Subbarao , Jennifer Brown , Walid Heneine , William M. Switzer
Inventor： Margaret E. Callahan , Thomas M. Folks , Paul Sandstrom , Shambavi Subbarao , Jennifer Brown , Walid Heneine , William M. Switzer
IPC: C12Q106
CPC classification number: C07K14/005 , A61K48/00 , C12N7/00 , C12N15/86 , C12N2740/17021 , C12N2740/17022 , C12N2740/17043
Abstract: The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.
Abstract translation: 本发明包括从人分离的真菌病毒。 更具体地，将本发明的真菌病毒与暴露于非人类灵长类动物的人分离。 重要的是，本发明的真菌病毒或针对该病毒的抗体可用于检测体液中的真菌病毒或抗体的存在，相关病毒的致病性研究以及用于基因治疗的载体。 由于存在快速分裂的细胞和重组活病毒疫苗接种，本发明的真菌病毒也可用于治疗人体中的病症。
-
公开(公告)号：US5882912A
公开(公告)日：1999-03-16
申请号：US798071
申请日：1997-02-12
Applicant: Paul A. Sandstrom , Jennifer Brown , Thomas M. Folks , Walid Heneine , William M. Switzer
Inventor： Paul A. Sandstrom , Jennifer Brown , Thomas M. Folks , Walid Heneine , William M. Switzer
CPC classification number: C12N15/86 , C12N7/00 , A61K48/00 , C12N2740/17021 , C12N2740/17043
Abstract: The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies.
Abstract translation: 本发明包括从人分离的真菌病毒。 更具体地，将本发明的真菌病毒与暴露于非人类灵长类动物的人分离。 重要的是，本发明的真菌病毒或针对该病毒的抗体可用于检测体液中的真菌病毒或抗体的存在，相关病毒的致病性研究以及用于基因治疗的载体。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.025 seconds)
